title: [Study on the plasma plasminogen activators in patients with malignant gynecologic tumors].
abstract: Increased plasminogen activator (PA) secretion has been observed in malignant cells and tissue and PA is thought to be involved in the processes of tumorigenesis, cancer invasion and metastasis. Recently two types of plasminogen activator--tissue type PA(tPA) and urokinase type PA(uPA)--have been detected in human plasma. In this study, to investigate the relationship between circulating PA and the malignant state, we measured the plasma PA concentrations (PA activity, tPA and uPA antigen) in 69 women with gynecologic malignancies (cervical cancer 50, ovarian cancer 19). These concentrations were compared to those in control groups of 33 women with benign gynecologic tumors (uterine tumor 8, ovarian tumor 25). An enzyme-linked immunoassay for tPA and uPA antigens was performed by the modified method described by Takada et al. (1986). PA activity was measured by the sensitive spectrophotometric assay of Verheijen et al. (1982). The blood samples were taken from an arm vein with a minimum of venous occlusion before treatment. There was no correlation between PA activity or uPA antigen levels and the malignant state. However, in the case of uterine tumors, a significantly higher concentration of tPA antigen (10.5 +/- 5.1 ng/ml) was found in patients with cervical cancer, in stage IV, than in those in the benign group (5.2 +/- 2.0 ng/ml). Moreover the tPA antigen concentration in cervical cancer, stage IV, was higher than in stages 0-III.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Obstetrics and Gynecology, Kobe Central Municipal Hospital.
authors.forename: H
authors.initials: H
authors.lastname: Shimada
authors.forename: M
authors.initials: M
authors.lastname: Ikeuchi
authors.forename: M
authors.initials: M
authors.lastname: Suwa
authors.forename: T
authors.initials: T
authors.lastname: Michimoto
authors.forename: Y
authors.initials: Y
authors.lastname: Ono
authors.forename: S
authors.initials: S
authors.lastname: Tanada
authors.forename: K
authors.initials: K
authors.lastname: Himeno
authors.forename: T
authors.initials: T
authors.lastname: Hoshino
authors.forename: E
authors.initials: E
authors.lastname: Takashima
mesh_terms: D000941:Antigens / Q000097:blood; D005260:Female; D005833:Genital Neoplasms, Female / Q000097:blood* / Q000276:immunology / Q000473:pathology; D006801:Humans; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000097:blood / Q000276:immunology / Q000473:pathology; D010960:Plasminogen Activators / Q000097:blood*; D010959:Tissue Plasminogen Activator / Q000276:immunology; D014568:Urokinase-Type Plasminogen Activator / Q000276:immunology; D014594:Uterine Neoplasms / Q000097:blood / Q000276:immunology / Q000473:pathology
chemical_list: D000941:Antigens; D010960:Plasminogen Activators; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator